Full TitleA Phase II Study of Cabozantinib in Patients with RET Fusion-Positive Advanced Non-Small Cell Lung Cancers
KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib is inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.
In this study, researchers are evaluating the safety and effectiveness of cabozantinib in patients with advanced non-small cell lung cancers that contain the KIF5B/RET gene. Cabozantinib is a pill that is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of metastatic or inoperable non-small cell lung cancer that contains the KIF5B/RET gene.
- At least 3 weeks must have passed since completion of prior chemotherapy, 2 weeks since other targeted drugs, and 3 months since radiation therapy to the chest and entry into the study.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Alexander Drilon at 646-888-4206.